Drug Profile
PG 116800
Alternative Names: PG 530742Latest Information Update: 06 Apr 2010
Price :
$50
*
At a glance
- Originator Procter & Gamble
- Class Heart failure therapies; Hydroxamic acids
- Mechanism of Action Metalloprotease inhibitors; Metalloprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Osteoarthritis
Most Recent Events
- 18 Apr 2005 Data presented at the 54th Annual Scientific Sessions of the American College of Cardiology (ACC-2005) have been added to the Adverse events and Heart Failure pharmacodynamics sections
- 17 Mar 2004 Data presented at the 53rd Annual Scientific Sessions of the American College of Cardiology (ACC-2004) have been added to the Heart Failure pharmacodynamics section
- 31 Aug 2003 Phase-II clinical trials in Heart failure in USA (PO)